Curated News
By: NewsRamp Editorial Staff
July 02, 2026

VERAXA Biotech Begins Cell Line Development for BiTAC-TCE Program with ATUM

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA's BiTAC-TCE program initiates cell line development, potentially enabling higher dosing and broader therapeutic window.
  • VERAXA uses ATUM's Leap-In Transposase to generate stable clonal cell lines for BiTAC-TCE, supporting IND/CTA-enabling activities.
  • VERAXA's 'AND-gated' BiTAC platform aims to reduce off-tumor toxicity, improving cancer treatment safety for patients.
  • VERAXA's BiTAC-TCE splits into two precursors that activate only when both bind tumor targets on the same cell.

Impact - Why it Matters

This development is crucial because VERAXA's conditional "AND"-gated BiTAC-TCE platform aims to reduce off-tumor toxicity—a major limitation of conventional T-cell engagers—potentially enabling safer and more effective cancer immunotherapies. The collaboration with ATUM to generate stable cell lines is a key step toward clinical trials, bringing this innovative approach closer to patients who need better treatment options with fewer side effects.

Summary

VERAXA Biotech (NASDAQ: VRXA) has announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines that will support IND/CTA-enabling activities and future clinical development. This collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.

VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This innovative approach addresses a key challenge in cancer immunotherapy: balancing efficacy with safety.

VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). For more details, visit the full press release at https://ibn.fm/FCIlk and the company’s newsroom at http://ibn.fm/VRXA.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Begins Cell Line Development for BiTAC-TCE Program with ATUM

blockchain registration record for this content.